People news: Cephalon and PhRMA

Share this article:
Cephalon named J. Kevin Buchi CEO and a member of the company's board of directors. Buchi, who was previously COO and CFO at the company and has led business development for the past seven years, replaces founder Frank Baldino in that role. Baldino died last week at age 57. Cephalon said the board will address the role of chairman in the future, and William Egan will continue to serve as the company's independent presiding director.

PhRMA named four new members to its board of directors, including: Ian Read, Pfizer's president and CEO; Jerzy Gruhn, president of Novo Nordisk in the US; Mark Iwicki, president and COO of Sunovion Pharmaceuticals, and Staffan Schuberg, president of Lundbeck's US unit.  
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.